Recombinant lactococcus lactis for secreting and expressing Dermatophagoides pteronyssinus allergen Derp2 and application of recombinant lactococcus lactis

Abstract

The invention relates to an optimized gene mderp2 obtained by carrying out codon optimization onto a gene of primary allergen Derp2 of the Dermatophagoides pteronyssinus, a recombinant expression plasmid pN8148-SD constructed based on the gene for secreting and expressing allergen Derp2 and recombinant lactococcus lactis L.lactis SD (preservation number as CGMCC (China General Microbiological Culture Collection Center) No.8223). Western blot results show that the recombinant lactococcus lactis L.lactis SD disclosed by the invention can realize secretion and expression of the allergen Derp2; meanwhile, an animal experiment result shows that orally-taken recombinant lactococcus lactis L.lactis SD can increase level of regulatory T cells in a mouse spleen, and can lower anaphylactic reaction caused by dust mite allergen Derp2 in the mouse body, and has a better preventive effect.

Description

Background technique [0001] Allergic diseases are clinically common and frequently-occurring diseases, and are currently a major worldwide health problem. Among the many inhaled allergens that cause allergic diseases, dust mites are one of the important factors leading to respiratory allergic diseases. Dust mite is a kind of organism with complex structure and composition. At present, dozens of allergens have been initially identified from hundreds of proteins of dust mite; allergen Derp2 is one of the most important allergens, about 80%- 90% of patients with dust mite allergy develop an allergic reaction to Derp2. Specific immunotherapy (SIT) is considered the most effective treatment for allergies, but successful immunotherapy depends on high-quality allergens. At present, the crude extract of dust mite used clinically for diagnosis and treatment contains a large amount of non-specific impurities, which seriously hinders the clinical application of dust mite allergen reage...

AI Technical Summary

Problems solved by technology

At present, the crude extract of dust mite used clinically for diagnosis and treatment contains a large amount of non-specific impurities, which seriously hinders the clinical application of dust mite allergen reagents

In order to obtain high-quality allergens, isolate and purify allergens from natural products (patent application number: 200410022961.9), the operation is complicated and the purity is not high, and the repeatability is poor; : 201210139240.0), yeast and other expression systems to express the allergen Derp2 is considered a feasible strategy, but its safety and subsequent purification of allergens limit the practical application of these expression systems

Images